Identifying Prognostic Factors in Mycosis Fungoides and Sezary Syndrome

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to develop a prognostic index model for mycosis fungoides and Sezary syndrome by collecting standardized clinical data from various institutions. The goal is to identify low- and high-risk groups for survival, which could lead to improved patient care and outcomes. Participants will include patients diagnosed with advanced stages of these conditions within six months of presentation. The study will utilize data from multiple centers to enhance the robustness of the findings.

Why it matters

Who can join: the full rules

Inclusion Criteria

* Diagnosis of advanced stage MF or SS (Stages IIB - IVB) within 6 months of presentation to the participating center
* Patients that are expected to have care administered at the participating center or jointly with referring physician(s) where follow-up data would be available

Exclusion Criteria

* Patients diagnosed with early stage MF/SS (Stages IA-IIA) before progressing to advanced stage
* Patients diagnosed with advanced MF/SS more than 6 months prior to initial presentation to the participating center
* Exclude one-time consultation type of new patients.

Where it's running

• City of Hope
  Duarte, California, United States Recruiting
• Stanford University, School of Medicine
  Palo Alto, California, United States Recruiting
• University of Iowa
  Iowa City, Iowa, United States Recruiting
• Hackensack University Medical Center
  Hackensack, New Jersey, United States Recruiting
• University of Pittsburg
  Pittsburgh, Pennsylvania, United States Recruiting
• University of Texas Southwestern
  Dallas, Texas, United States Recruiting

Study contacts

• Principal investigator: Youn H Kim, MD — Stanford University
• Study coordinator: Tatiana Neal
• Email: tatianan@stanford.edu
• Phone: 650-709-7838

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BEX101 CAR-T at the bedside for relapsed or refractory B-cell NHL

  A bedside, on-site CAR-T therapy called BEX101 is being tested in adults with relapsed or refractory B-cell non-Hodgkin’s lymphoma to see if it is safe and can help control the disease.

  Recruiting Phase 1/2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07882641

• KSVCBD Injection for B-cell Non-Hodgkin's Lymphoma with CD19 and/or BCMA

  This study tests KSVCBD, a CAR-T therapy made inside the body, in adults with relapsed or refractory B-cell non-Hodgkin's lymphoma to see if it is safe and can help fight the cancer.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07620314

• Comparing antibiotics and immunoglobulin to prevent infections in blood cancers

  This project tests whether immunoglobulin or antibiotic strategies better prevent infections in adults with blood cancers.

  Recruiting at 3 sites Phase 2/3 Monash University · Adelaide, South Australia and 2 other locations · NCT07202052

• Poteligeo (mogamulizumab) for adults with mycosis fungoides or Sézary syndrome

  This project will try Poteligeo (mogamulizumab) in adults with mycosis fungoides or Sézary syndrome who have had at least one prior systemic therapy to see how safe and effective it is in routine care in Korea.

  Recruiting at 5 sites Kyowa Kirin Co., Ltd. · Busan, Busan Metropolitan City and 5 other locations · NCT07132567

• Golidocitnib treatment for relapsed indolent T/NK-cell lymphomas

  This study is testing if a new oral medication called Golidocitnib can help people with relapsed indolent T/NK-cell lymphomas feel better after other treatments haven't worked.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality and 1 other locations · NCT06716658

• Using Riluzole to Help Breast Cancer Survivors with Cognitive Issues

  This study is testing if the medication riluzole can help breast cancer survivors who are having trouble with thinking and memory feel better.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT06580002

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.